Tracie Oliver - Arrowhead Pharmaceuticals Chief Officer
| HDP1 Stock | EUR 19.36 0.31 1.63% |
Insider
Tracie Oliver is Chief Officer of Arrowhead Pharmaceuticals
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Tracie Oliver Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tracie Oliver against Arrowhead Pharmaceuticals stock is an integral part of due diligence when investing in Arrowhead Pharmaceuticals. Tracie Oliver insider activity provides valuable insight into whether Arrowhead Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Arrowhead Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Arrowhead Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tracie Oliver over six months ago Disposition of 9394 shares by Tracie Oliver of Arrowhead Pharmaceuticals at 25.28 subject to Rule 16b-3 |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1285) % which means that it has lost $0.1285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4043) %, meaning that it generated substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alison Martin | Zurich Insurance Group | 49 | |
| Christine BA | Insurance Australia Group | N/A | |
| Neil BSc | Insurance Australia Group | N/A | |
| BCom BCom | Insurance Australia Group | 54 | |
| Tulsi Naidu | Zurich Insurance Group | 50 | |
| Jeffrey Dailey | Zurich Insurance Group | 66 | |
| Mario Greco | Zurich Insurance Group | 64 | |
| Peter Horton | Insurance Australia Group | N/A | |
| Peter Giger | Zurich Insurance Group | 59 | |
| Ericson Chan | Zurich Insurance Group | 57 | |
| MBA BS | Zurich Insurance Group | 53 | |
| Julie Batch | Insurance Australia Group | N/A | |
| Kristof Terryn | Zurich Insurance Group | 56 | |
| Sierra Signorelli | Zurich Insurance Group | 48 | |
| Amanda Whiting | Insurance Australia Group | N/A | |
| BAgr AMP | Insurance Australia Group | 57 | |
| George Quinn | Zurich Insurance Group | 57 | |
| BBUS CA | Insurance Australia Group | N/A | |
| Peter BCom | Insurance Australia Group | N/A | |
| Jarrod Hill | Insurance Australia Group | N/A | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracie Oliver, Chief Officer | ||
| Kenneth Myszkowski, Chief Officer | ||
| Christopher Anzalone, President CEO, Director | ||
| Javier MD, Chief Officer | ||
| PharmD JD, COO Counsel | ||
| Howard Lovy, Director Communications | ||
| Vincent CFA, Head VP | ||
| Mark Davis, Founder Calando | ||
| MBA MD, VP Medicine | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Shares Owned By Insiders | 4.93 % | |||
| Shares Owned By Institutions | 69.27 % | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X |
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in Arrowhead Stock
When determining whether Arrowhead Pharmaceuticals is a strong investment it is important to analyze Arrowhead Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Arrowhead Pharmaceuticals' future performance. For an informed investment choice regarding Arrowhead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.